Relationship between cardiovascular health and COPD andits impact on all-cause mortality in patients with COPD: analyses of NHANES 2005-2018

心血管健康与慢性阻塞性肺疾病(COPD)的关系及其对COPD患者全因死亡率的影响:基于2005-2018年美国国家健康与营养调查(NHANES)数据的分析

阅读:1

Abstract

BACKGROUND: Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) are intimately connected. A recently developed measure called Life's Essential 8 (LE8) is used to evaluate cardiovascular health (CVH). We aimed to investigate the relationship between LE8 and the prevalence of COPD, and the association between LE8 and all-cause mortality in individuals with COPD. METHODS: The National Health and Nutrition Examination Survey (NHANES) 2005-2018 was the source of the data used in our investigation. The participants were divided into three groups according to their LE8 scores: low (< 50), moderate (50-79), and high (≥ 80) CVH. Weighted logistic regression models and restricted cubic spline (RCS) curves were used to examine the relationship between LE8 score and the prevalence of COPD. To determine whether the results were stable, we used subgroup and sensitivity analyses. Furthermore, we evaluated the association between LE8 and all-cause mortality in COPD patients using a weighted Cox regression analysis. RESULTS: Weighted logistic regression analysis of the fully adjusted model indicated that a higher LE8 score was associated with a lower prevalence of COPD (OR = 0.75; 95% CI, 0.71-0.79). The RCS curves showed a linear negative association between them. LE8 score was negatively correlated with the prevalence of COPD across all subgroups, and this negative correlation was significant in those younger than 60 years old. The sensitivity analysis's results were consistent with the primary findings. Furthermore, weighted Cox regression analysis of the fully adjusted model showed that LE8 score was negatively associated with all-cause mortality in COPD patients (HR = 0.81, 95% CI = 0.74-0.89). CONCLUSIONS: LE8 score was negatively associated not only with the prevalence of COPD, but also with all-cause mortality in patients with COPD. CLINICAL TRIAL NUMBER: Not applicable.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。